ClinicalTrials.gov record NCT06742697
Flexibility, Resistance, Aerobic, Movement Execution Training in Adults With Hereditary Spastic Paraplegia
Flexibility, Resistance, Aerobic, Movement Execution (FRAME) Training Program to Improve Gait Capacity in Adults With Hereditary Spastic Paraplegia: Protocol for a Single-cohort Feasibility Trial
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
This single-group interventional study tests a structured exercise program (FRAME) for adults with Hereditary Spastic Paraplegia (HSP). Twenty adults will do 10–16 therapist‑guided sessions (60–120 minutes each), then receive a home‑exercise package; assessments occur before, after, and three months later. Core eligibility includes being an adult with HSP who can walk without physical assistance; people who had botulinum toxin treatment or lower‑limb surgery in the prior six months or who cannot undertake moderate physical activity are excluded.
What it is studying. The study tests whether a 10–16 session, therapist‑guided FRAME program (flexibility, resistance, movement execution, and high‑intensity interval aerobic training) is feasible to deliver to adults with HSP and whether it is associated with changes in gait endurance (6‑minute walk) and gait speed (10‑metre walk).
What the researchers hope to learn. Primary scientific goals are to assess feasibility: recruitment, adherence (≥75% of planned sessions and minimum 10 sessions), retention (≥75% completing the study), safety (absence of serious adverse events), and patient satisfaction. Secondary goals are to measure changes in walking endurance (6MWT) and walking speed (10MWT); exploratory measures include functional scales, joint range of motion, strength, and balance.
What this study is about
The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.
Hereditary Spastic Paraplegia (HSP) is a diverse group of genetic neurological conditions causing progressive weakness and spasticity in the lower limbs, severely reducing balance and gait capabilities. There is currently a lack of structured neurorehabilitation programs aimed at improving gait in adults with HSP. This protocol seeks to assess the feasibility and effectiveness of a structured training approach focusing on flexibility, muscle strength, motor control, balance, and aerobic capacity. To this end, twenty adults diagnosed with HSP will engage in 10 to 16 sessions, each lasting 60 to 120 minutes, guided by a therapist once or twice a week, depending on individual preferences. At the end of the program, participants will receive a transfer package, including written instructions (a manual) and video tutorials, to encourage ongoing exercise at home. Assessments will occur before the intervention (T0), immediately after (T1), and three months later (T2). The primary outcomes will measure the feasibility of the program, including recruitment, retention, adherence, the absence of adverse events, and patient satisfaction. Secondary outcomes will focus on improvements in gait capabilities such as gait endurance and gait speed.
Interventions being studied
Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.
- Behavioral
- Flexibility, Resistance, Aerobic, Movement Execution training
Eligibility
The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.
Inclusion criteria
- Adults diagnosed with Hereditary Spastic Paraplegia.
- Presence of any functional deficit in the lower limbs that affects walking, such as muscle weakness, hypertonia, or balance issues.
- Ability to walk without the need for physical contact with another person, as defined by a Functional Ambulation Category score of 3 or higher.
- Ability to understand simple instructions, comprehend the purpose of the study, willingness to participate and undergo at least 10 treatment sessions, eligible and willing to sign the informed consent.
Exclusion criteria
- Botulinum toxin or surgery to treat lower limb hypertonia in the six months prior to enrollment in the study.
- Contraindications for moderate physical activity, such as stretching exercises, muscle strength training, and aerobic capacity training.
Study description and what participation involves
The study's detailed description, as published on ClinicalTrials.gov.
Show the detailed description from the registry
INTRODUCTION: Hereditary Spastic Paraplegia (HSP) is a heterogeneous group of inherited neurological disorders characterized by progressive weakness and spasticity in the lower limbs, which significantly impairs walking abilities (endurance and speed). Despite several specific interventions for particular deficits already having been studied, there is currently a lack of comprehensive and structured neurorehabilitation programs designed to improve walking function in these patients. Therefore, this protocol aims to explore the feasibility and effectiveness of a composite training approach focused on improving flexibility, muscle strength, motor control, balance, and aerobic capacity. STUDY OBJECTIVES: Primary endpoint: Feasibility of the study, assessed by the following: Sufficient recruitment rate, with 20 patients enrolled within 24 months from the study's initiation. Adequate adherence to the treatment plan, defined by the completion of at least 75% of the planned treatment sessions, with a minimum of 10 treatment sessions. Sufficient patient retention, defined as at least 75% of enrolled patients completing the study with adequate treatment adherence. Absence of serious adverse events related to patient participation in the study. Patient satisfaction with the healthcare received during the study. Secondary endpoint: Therapeutic efficacy of the study, assessed by: Improvement in walking endurance (6-Minute Walk Test). Improvement in walking speed (10-Meter Walk Test). Exploratory objectives: Improvement in overall functional condition (Spastic Paraplegia Rating Scale and the Hereditary Spastic Paraplegia - Self Notion and Perception Questionnaire). Improvement in passive joint range of motion in the lower limbs (goniometer). Improvement in lower limb muscle strength (5 Times Sit-to-Stand Test). Improvement in standing balance (Functional Reach Test and stabilometric platform). STUDY DESIGN: Open-label, non-randomized, uncontrolled interventional study. STUDY POPULATION: Hereditary Spastic Paraplegia patients SAMPLE SIZE: 20 patients ELIGIBILITY: Inclusion criteria: Adults diagnosed with Hereditary Spastic Paraplegia. Presence of any functional deficit in the lower limbs affecting walking, such as muscle weakness, hypertonia, or balance issues. Ability to walk independently, without physical assistance from another person, defined by a Functional Ambulation Category score of 3 or higher. Ability to understand simple instructions, comprehend the purpose of the study, willingness to participate, commitment to at least 10 treatment sessions, and suitability for signing the informed consent. Exclusion criteria: Use of botulinum toxin or surgery to treat lower limb hypertonia within six months prior to study enrollment. Contraindications for moderate physical activity, including stretching exercises, muscle strengthening, and aerobic training. Withdrawal Criteria: Voluntary withdrawal by the patient. Occurrence of adverse events or health issues that prevent continuation of the treatment plan. Patient Replacement: Recruitment will continue until 20 subjects are enrolled. Any patients who withdraw from the study will not be replaced. METHODS: Twenty adults diagnosed with HSP will participate in 10 to 16 therapist-guided sessions, each lasting 60 or 120 minutes, occurring once or twice a week depending on individual choice and capabilities. At the conclusion of the study, participants will receive an information package (manual and video tutorials) to support long-term home exercise. Evaluations will take place at three time points: before the intervention (T0), immediately after the intervention (T1), and three months post-intervention (T2). The primary objectives will focus on assessing the study's feasibility (recruitment, retention, adherence, absence of adverse events, and patient satisfaction). Secondary outcomes will evaluate improvements in walking ability and specific contributing factors, such as reduced spasticity, increased muscle strength, and improved balance. INTERVENTION: FRAME training is composed of four key components: Component 1: Flexibility. To decrease muscle tone and enhance mobility, the therapist will apply a combination of stretching exercises and electrical stimulation, targeting areas such as the triceps surae, adductors, rectus femoris, and hamstrings. Electrical stimulation will utilize biphasic, high-frequency sensory stimulation (100 Hertz, pulse width 200 µs, and intensity just below the motor threshold) for a duration of 30 minutes, combined with stretching activities. Component 2: Resistance Training (and Balance). The resistance training will focus on strengthening muscles typically weakened in individuals with Hereditary Spastic Paraplegia (HSP), especially the proximal muscles of the hip and trunk. To promote muscle engagement and improve balance and coordination, core stability and resistance exercises will be performed under conditions of mild instability. These exercises will be carried out in sitting or standing positions, rather than lying down, to optimize muscle activation. Component 3: Movement Execution (and Balance). Gait training will be based on motor learning principles such as repetitive, task-oriented practice, variable practice, and graded practice. Graded practice involves breaking down a complex movement into simpler segments, practicing each segment until proficiency is achieved, and then progressively combining them into more complex sequences. Patients will be challenged with standing balance exercises while working on specific gait impairments. Gait training will involve varying walking patterns, including fast, slow, sidewalk walking, walking backward, and stair climbing. Component 4: Aerobic Training via High-Intensity Interval Training (HIIT). HIIT consists of brief, intense aerobic efforts using large muscle groups, followed by rest periods of equal length. HIIT has been found to produce better cardiovascular results with a lower perceived level of effort compared to moderate-intensity aerobic exercise. In this protocol, patients will perform 30-second high-intensity intervals followed by 30 seconds of passive rest, repeated 10 times in two sets. Each session will begin with a 5-minute warm-up, include a 5-minute rest between sets, and conclude with a 5-minute cool-down. Patients will participate in the modality most suitable for consistent training, such as walking, running, cycling, or squatting. RELEVANCE: This protocol is significant for providing clinicians with valuable insights into the feasibility and potential effectiveness of a comprehensive, clinically-oriented program designed to improve walking ability in adults with Hereditary Spastic Paraplegia. It also aims to inform future translational research studies in the field.
AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
Take part in 10–16 therapist‑guided sessions (each 60–120 minutes) delivered once or twice weekly. Sessions combine flexibility (stretching plus sensory electrical stimulation), resistance and balance work, task‑oriented gait/motor‑learning training, and short high‑intensity aerobic intervals. Assessments happen before the program (T0), immediately after (T1), and three months later (T2) and include walking tests such as the 6‑Minute Walk Test and 10‑Metre Walk Test plus other functional measures. Participants receive a take‑home package (manual and video tutorials); they may withdraw voluntarily or if adverse events or health issues prevent continuing.
How the study is structured. An open‑label, single‑group interventional trial: all participants receive the same personalized FRAME training. There is no randomization or control group. Measurements are taken before the program (T0), immediately after the program (T1), and 12 weeks after T1 (T2). The planned sample size is 20 adults.
Questions you could ask
These questions are suggestions for a conversation with the study team or your own clinician, not advice.
- The listed sites are in Italy. Is any of them reachable for me, and does the study help with travel?
- Which of the eligibility criteria would need to be checked with tests before I could join?
More on hereditary spastic paraplegia
Important dates
- Study start
- Dec 23, 2024
- Primary completion
- December 2026 (estimated)
- Study completion
- April 2027 (estimated)
- Target enrollment
- 20 participants (estimated)
- Last updated on registry
- Jan 30, 2025
- Data verified
- Oct 10, 2026
Sponsor and research team
The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.
- Lead sponsor
- IRCCS Eugenio Medea
Central study contact
If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.
- Leonardo Boccuni, PhD 📞 003904384141 ✉ leonardo.boccuni@lanostrafamiglia.it
- Marco Bortolini, BSc 📞 003904389062 ✉ marco.bortolini@lanostrafamiglia.it
Participating sites (2)
- Scientific Institute, IRCCS E. Medea, Department of Bosisio Parini, Lecco, Italy.Recruiting
Bosisio Parini, Lombardy, 23842 · Italy
- Eleonora Diella, BSc · 0039031877589 · eleonora.diella@lanostrafamiglia.it
- Leonardo Boccuni, PhD · 003904384141 · leonardo.boccuni@lanostrafamiglia.it
- Eleonora Diella, BSc
- Scientific Institute, IRCCS E. Medea, Department of Pieve di Soligo, Treviso, ItalyRecruiting
Pieve di Soligo, Veneto, 31053 · Italy
- Leonardo Boccuni, PhD · 003904384141 · leonardo.boccuni@lanostrafamiglia.it
- Marco Bortolini, BSc · 003904389062 · marco.bortolini@lanostrafamiglia.it
- Leonardo Boccuni, PhD
Terms used on this page · explanations by MedicalUpdates.ai
- adverse events
- Any unwanted medical problem that happens during a study, whether or not it was caused by the treatment. A 'serious' adverse event is one that meets specific criteria, such as causing death, being life-threatening, requiring or prolonging hospital admission, causing significant disability, or another medically important outcome.
- informed consent
- The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
- enrollment
- The number of participants a study plans to include, or has included. 'Estimated' means the planned number; 'actual' means the number who joined.
- Contraindications
- A reason a particular test or treatment should not be used for a person, for example a metal implant that rules out an MRI scan.
- Inclusion Criteria
- The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
- Exclusion Criteria
- The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
- Primary endpoint
- The main result the study is designed to measure and report on. Other results, called secondary outcomes, are also collected.
- Secondary endpoint
- An additional result the study measures alongside the primary outcome, for example quality of life or a laboratory value.
- 6-Minute Walk Test
- A test of how far a person can walk on a flat surface in six minutes. It is used to measure stamina and to track change over time.
- Open-label
- No masking is used, so the assigned intervention is not deliberately hidden from participants or study staff.
- randomized
- Participants are assigned to the study groups by chance, like a coin toss, rather than chosen by the doctor or the participant. This is done so the groups are comparable.
The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.
← Back to clinical trials